Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070333 | 0.78 | MAPT (0.56) | ALDH1A1CYP3A4XDHPARP1MAPT | |
| SCHEMBL8751990 | 0.78 | ALDH1A1 (0.39) | ALDH1A1GLACYP3A4NAMPTXDH | |
| SCHEMBL163689 | 0.67 | — | — | |
| SCHEMBL13292077 | 0.65 | PTPRC (0.52) | ALDH1A1CYP3A4MAPTADRA2AADRA2B | |
| Ammonia Solution, Strong SCHEMBL30767694 | 0.65 | — | — | |
| SCHEMBL308403 | 0.65 | ALDH1A1 (0.47) | ALDH1A1GLACYP3A4NAMPTXDH | |
| SCHEMBL10113803 | 0.64 | MAPT (0.43) | ALDH1A1CYP3A4XDHMAPTADRA2A | |
| SCHEMBL438963 | 0.64 | MAPT (0.64) | ALDH1A1CYP3A4MAPTADRA2AADRA2B | |
| SCHEMBL11747969 | 0.64 | CYP19A1 (0.44) | ALDH1A1MAPTADRA2AADRA2BADRA2C | |
| SCHEMBL6781137 | 0.64 | TSHR (0.46) | ALDH1A1MAPTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119409702-A | Synthesis method of dipyridamole key intermediate | 南通森萱药业有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119409702-A | Synthesis method of dipyridamole key intermediate | 南通森萱药业有限公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024017863-A1 | NOVEL PYRIMIDINYL AND TRIAZINYL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| US-8093380-B2 | Viricides, antitumor agents, anticancer agents | PHARMASSET, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2010038803-A1 | 2-INDOLEACRYLAMIDE ANALOGUE | 持田製薬株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| EP-2166849-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | Miikana Therapeutics, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010010934-A1 | HETEROCYCLIDENE DERIVATIVE HAVING P-SUBSTITUTED ARYLACETAMIDE | 持田製薬株式会社 (JP) | 2010-01-28 | — | — | WO | disclosed |
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008154026-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1545545-A4 | COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS | PHARMASSET INC (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1545545-A2 | COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS | Pharmasset, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082574-A1 | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections | PHARMASSET, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004013300-A2 | COMPOUNDS WITH THE BICYCLO[4.2.1]NONANE SYSTEM FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET INC. (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082574-A1 | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections | CYP4B1, HAVCR2, CYP2S1 | ALDH1A1 1212/4885GLA 4126/4885CYP3A4 13/4885 |
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | AURKC, AURKA, AURKB | ALDH1A1 3400/4885GLA 3124/4885CYP3A4 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.